HIV vaccines--where are we going? (Q40859520)

24 September 2017

1 reference

title

HIV vaccines--where are we going? (English)

1 reference

24 September 2017

Heilman CA

1

1 reference

PubMed ID

9585205

24 September 2017

Baltimore D

series ordinal

2

1 reference

PubMed ID

9585205

24 September 2017

language of work or name

English

0 references

publication date

1 May 1998

1 reference

24 September 2017

1 reference

24 September 2017

4

1 reference

24 September 2017

5 Suppl

1 reference

24 September 2017

532-534

1 reference

https://scigraph.springernature.com/pub.10.1038/nm0598supp-532

24 September 2017

0 references

cites work

A vaccine for HIV type 1: the antibody perspective

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

Phenotypic analysis of antigen-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

Animal models of human immunodeficiency virus infection. Public Health Service Animal Models Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

Chemokines and HIV-1 second receptors. Confluence of two fields generates optimism in AIDS research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

7 January 2021

Genotypic and phenotypic characterization of HIV-1 patients with primary infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

7 January 2021

Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

7 January 2021

Development of HIV-1 group-specific neutralizing antibodies after seroconversion

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

7 January 2021

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

7 January 2021

Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

7 January 2021

Evaluation of Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Primary Isolates by Neutralization Assays: Performance Criteria for Selecting Candidate Antibodies for Clinical Trials

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

7 January 2021

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

7 January 2021

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

7 January 2021

Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

7 January 2021

Early phases of HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

7 January 2021

HIV-specific cellular and humoral immune responses in primary HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

7 January 2021

Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

7 January 2021

Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

7 January 2021

Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

7 January 2021

Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

7 January 2021

Evidence for HIV-1 infection in rabbits. A possible model for AIDS.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-532

7 January 2021

Identifiers

DOI

10.1038/NM0598SUPP-532

1 reference

24 September 2017

1 reference

PubMed ID

9585205